Overview
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9 genome-editing technology. Its stated mission is “to create transformative gene-based medicines for serious human diseases.” Its work spans ex vivo and in vivo gene editing, cell therapies, and regenerative medicine.[1][2]
Its defining marketed therapy is CASGEVY (exagamglogene autotemcel), developed with Vertex, an ex vivo gene-edited cell therapy for eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. The company also develops a broader pipeline of gene-editing and cell-therapy candidates.[3][4][5]
Incorporated in Switzerland in 2013, CRISPR Therapeutics is headquartered in Zug, with U.S. research and development operations in Boston and San Francisco and a cell-therapy manufacturing facility in Framingham, Massachusetts.[6][7] For the year ended December 31, 2025, it reported total revenue of $3.51 million, compared with $37.31 million in 2024; the cited filing reports no employee headcount.[8] [1][2][3][4][5][6][7][8][8]
Products & services
CRISPR Therapeutics’ commercial product is CASGEVY (exa-cel; exagamglogene autotemcel), developed with Vertex for sickle cell disease and transfusion-dependent beta thalassemia. It is an autologous, ex vivo CRISPR/Cas9 therapy: a patient’s blood stem cells are edited at the erythroid-specific BCL11A enhancer to increase fetal hemoglobin, then administered back to the patient. Vertex manufactures CASGEVY, and the companies share program costs and worldwide revenue equally.[9][10][11]
Its in vivo editing candidates use lipid nanoparticle delivery. CTX310 targets ANGPTL3 and is being studied for lipid disorders; CTX340 targets AGT for refractory hypertension; CTX321 targets LPA for elevated Lp(a); and CTX460 uses SyNTase editing to target SERPINA1 for alpha-1 antitrypsin deficiency.[12][13][14][15][16]
Zugocabtagene geleucel (zugo-cel, formerly CTX112) is an allogeneic CD19 CAR-T candidate, engineered with CRISPR/Cas9 and under investigation for autoimmune diseases and B-cell malignancies. CTX213 is a deviceless beta-cell replacement candidate for type 1 diabetes, using unencapsulated precursor islet cells derived from edited iPSCs. CTX611 (SRSD107), developed with Sirius, is a long-acting siRNA targeting FXI mRNA for anticoagulant effects; it is not a CRISPR gene-editing therapy.[17][18][19][20][21][22][23]
No service offering or product-specific share of company performance is disclosed in the cited materials. Reported Q2 2026 revenue was primarily collaboration revenue, but that figure is not identified as product sales.[24] [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]
Geographic presence
CRISPR Therapeutics AG is headquartered in Zug, Switzerland, and identifies Boston, Massachusetts, as its U.S. research and development headquarters. The company also has lab and office space in San Francisco, California, and an approximately 50,000-square-foot cell-therapy manufacturing facility in Framingham, Massachusetts.[7][25][26][6] [7][25][26][6]
Business segments
CRISPR Therapeutics AG reports one operating and reportable segment: the discovery, development and commercialization of genome-editing therapies. Accordingly, 100% of its reported business is included in this single segment; the company does not report revenue or other contribution percentages for separate franchises.[27][28]
The company’s disclosed areas of therapeutic focus include hemoglobinopathies, in vivo approaches, CAR-T and regenerative medicine, pursued through ex vivo or in vivo editing. These are areas of focus, not separately reported business segments, and no percentage contribution is disclosed for them.[28][29] [27][28][29]
Company history
CRISPR Therapeutics was incorporated in Switzerland as Inception Genomics AG on 31 October 2013 and renamed CRISPR Therapeutics AG in April 2014. Co-founded by Emmanuelle Charpentier, Rodger Novak and Shaun Foy, the company set out to develop medicines using CRISPR/Cas9 gene-editing technology.[30][31] In 2015, it established collaborations with Bayer and Vertex; the Bayer partnership led to the 2016 formation of Casebia Therapeutics, a 50/50 joint venture.[32][33][34][35] The company completed its IPO in October 2016, listing on Nasdaq under the ticker CRSP.[36]
Samarth Kulkarni became CEO in December 2017.[37] Its collaboration with Vertex advanced CTX001—later named exa-cel and then CASGEVY—into clinical trials for sickle cell disease and beta-thalassemia. The first beta-thalassemia patient was infused in 2019, and the companies reported initial positive results in patients with both conditions that year.[38][39][40] In 2021, Vertex assumed responsibility for worldwide development, manufacturing and commercialization of the program under an amended agreement.[41]
CASGEVY became the first approved CRISPR gene-editing therapy when the UK authorized it in November 2023. The FDA approved it for sickle cell disease in December 2023 and transfusion-dependent beta-thalassemia in January 2024.[42][43][44] [33][34][38][39][30][31][32][35][36][37][40][41][42][43][44]
Sources
- CRISPR Therapeutics AG — Full financial report (2025 Y)
- CRISPR Therapeutics AG — Full financial report (2026 Q 2)
- CRISPR Therapeutics AG — Press release (2026 Q 2)
- crisprtx.gcs-web.com[30]
- crisprtx.com[31]
- ir.crisprtx.com[32]
- CRISPR Therapeutics AG — Full financial report (2016 Y)[33][34]
- crisprtx.com[35]
- crisprtx.com[36]
- crisprtx.com[37]
- CRISPR Therapeutics AG — Full financial report (2019 Y)[38][39]
- crisprtx.com[40]
- crisprtx.com[41]
- crisprtx.com[42]
- crisprtx.com[43]
- crisprtx.com[44]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore CRISPR Therapeutics AG in Finbar ↗